Identifying barriers and facilitators for implementing harm reduction strategies for methamphetamine use into hospital settings.
harm reduction
health equity
hospitals
nursing
qualitative research
substance use
Journal
Frontiers in health services
ISSN: 2813-0146
Titre abrégé: Front Health Serv
Pays: Switzerland
ID NLM: 9918334887706676
Informations de publication
Date de publication:
2023
2023
Historique:
received:
01
12
2022
accepted:
17
01
2023
entrez:
17
3
2023
pubmed:
18
3
2023
medline:
18
3
2023
Statut:
epublish
Résumé
Harm reduction strategies for substance use disorder are not currently offered in Canadian hospitals. Previous research has suggested that substance use may continue to occur which can lead to further complications such as new infections. Harm reduction strategies may be a solution to this issue. This secondary analysis aims to explore the current barriers and potential facilitators for implementing harm reduction into the hospital from the perspective of health care and service providers. Primary data was collected from 31 health care and service providers who participated in a series of virtual focus groups and one-to-one interviews regarding their perspectives on harm reduction. All staff were recruited from hospitals in Southwestern Ontario, Canada from February 2021 to December 2021. Health care and service professionals completed a one-time individual interview or a virtual focus group using an open-ended qualitative interview survey. Qualitative data was transcribed verbatim and analyzed using an ethnographic thematic approach. Themes and subthemes were identified and coded based on responses. Attitude and Knowledge, Pragmatics, and Safety/Reduction of Harm were identified as the core themes. Attitudinal barriers such as stigma and lack of acceptance were reported but education, openness and community support were regarded as potential facilitators. Cost, space, time and availability of substances on site were regarded as Pragmatic barriers but potential facilitators such as organizational support, flexible harm reduction services and a specialized team were identified. Policy and liability were perceived as both a barrier and a potential facilitator. Safety and impact of substances on treatment were considered as both a barrier and a potential facilitator but sharps boxes and continuity of care were regarded as potential facilitators. Although barriers in implementing harm reduction in hospital settings exist, there are opportunities to facilitate change. As identified in this study, feasible and achievable solutions are available. Education on harm reduction for staff was considered to be a key clinical implication in facilitating harm reduction implementation.
Identifiants
pubmed: 36926504
doi: 10.3389/frhs.2023.1113891
pmc: PMC10012827
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1113891Informations de copyright
© 2023 Forchuk, Serrato and Scott.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Metab Brain Dis. 2016 Feb;31(1):53-62
pubmed: 26671551
Int J Drug Policy. 2021 Apr;90:103080
pubmed: 33340947
Addict Behav. 2009 Apr;34(4):380-5
pubmed: 19097704
PLoS One. 2019 Oct 24;14(10):e0224335
pubmed: 31648259
Aust Prescr. 2016 Jun;39(3):96-100
pubmed: 27346918
Int J Ment Health Nurs. 2017 Oct;26(5):437-444
pubmed: 28960736
J Manag Care Spec Pharm. 2021 Feb;27(2):137-146
pubmed: 33506729
Harm Reduct J. 2017 Jul 26;14(1):50
pubmed: 28747183
Int J Drug Policy. 2015 Feb;26 Suppl 1:S5-11
pubmed: 25727260
Addiction. 2019 Aug;114(8):1379-1386
pubmed: 30851220
Front Neurosci. 2015 Jan 12;8:445
pubmed: 25628526
Drug Alcohol Rev. 2008 May;27(3):253-62
pubmed: 18368606
Med Decis Making. 2001 Sep-Oct;21(5):357-67
pubmed: 11575485
J Subst Abuse Treat. 2020 Mar;110:59-65
pubmed: 31952629
Drug Alcohol Rev. 2019 May;38(4):423-427
pubmed: 31021491
Australas Psychiatry. 2019 Feb;27(1):14-17
pubmed: 30382752
Annu Rev Clin Psychol. 2010;6:591-606
pubmed: 20192791
J Drug Issues. 2013 Oct;43(4):468-482
pubmed: 26594058
CMAJ. 2020 May 4;192(18):E476-E479
pubmed: 32366467
Issues Ment Health Nurs. 2017 Jan;38(1):33-41
pubmed: 27936336
Arch Gen Psychiatry. 2011 Mar;68(3):271-82
pubmed: 21041607
Addict Health. 2014 Summer-Autumn;6(3-4):146-54
pubmed: 25984282
Epidemiol Infect. 2017 Mar;145(4):796-801
pubmed: 27927256
Drug Alcohol Depend. 2013 Dec 1;133(2):529-34
pubmed: 23932843
Int Emerg Nurs. 2009 Jan;17(1):3-14
pubmed: 19135010
JAMA Netw Open. 2020 Aug 3;3(8):e2012974
pubmed: 32785635
Metab Brain Dis. 2018 Apr;33(2):559-568
pubmed: 29224181
PLoS One. 2020 May 21;15(5):e0229208
pubmed: 32438390
PLoS One. 2016 Dec 21;11(12):e0168782
pubmed: 28002491
J Infect Prev. 2014 Sep;15(5):170-174
pubmed: 28989381
Emerg Med Australas. 2020 Oct;32(5):793-800
pubmed: 32356401
Addict Sci Clin Pract. 2018 Apr 9;13(1):8
pubmed: 29628018
Nurse Educ. 2020 Nov/Dec;45(6):321-325
pubmed: 32091475
Harm Reduct J. 2022 Feb 5;19(1):13
pubmed: 35120536
Can Pharm J (Ott). 2012 May;145(3):124-127.e2
pubmed: 23509527